Tennor Therapeutics
PublicTennor Therapeutics is now publicly traded
The data on this page reflects Tennor Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series D
May 26, 2026
Total Funding Raised
$110.89M
Company Overview
Tennor Therapeutics is a biotechnology research company that discovers and develops novel multi-functional drugs for the treatment of cancers and autoimmune diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Tennor Therapeutics Comparables
Compare Tennor Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gurnet Point Capital | 75% | |
| RedHill Biopharma | 73% | |
| Trellis Bioscience | 68% |
Tennor Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 26, 2026 | ||||
| Series E | Oct 16, 2024 | ||||
| Series D Extension | Jan 5, 2023 | ||||
| Series D | Feb 25, 2022 | ||||
| Series C Extension | Jun 5, 2020 | ||||
Series C | Sep 19, 2016 |
Tennor Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 中山创业投资有限公司 | Series E |
| AMR Action Fund | Series E |
| Yuanjing Investment | Series D Extension |
| Yanchuang Capital | Series D |
| Oriza Holdings | Series C Extension, Series B, Series D |
| Al Mal Investment Company | Series B |
| Northern Light Venture Capital | Series C |
Tennor Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access